<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Antimicrobial prophylaxis regimens for adult patients with chronic lymphocytic leukemia (CLL)*</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Antimicrobial prophylaxis regimens for adult patients with chronic lymphocytic leukemia (CLL)*</h1>
<div class="graphic"><div class="figure"><div class="ttl">Antimicrobial prophylaxis regimens for adult patients with chronic lymphocytic leukemia (CLL)*</div><div class="cntnt"><table cellspacing="0"><tbody> <tr> <td class="subtitle1_single">Antibacterial</td> </tr> <tr> <td class="indent1">Ciprofloxacin 500 or 750 mg orally twice daily</td> </tr> <tr class="divider_bottom"> <td class="indent1">Levofloxacin 500 or 750 mg orally once daily</td> </tr> <tr> <td class="subtitle1_single">Antifungal</td> </tr> <tr> <td class="indent1">Fluconazole<sup>¶</sup> 200 or 400 mg orally once daily</td> </tr> <tr> <td class="indent1">Posaconazole<sup>¶</sup> delayed-release tablets 300 mg (three 100 mg tablets) orally every 12 hours on the first day, followed by 300 mg (three 100 mg tablets) once daily starting on the second day</td> </tr> <tr class="divider_bottom"> <td class="indent1">Voriconazole<sup>¶</sup> 200 mg orally twice daily</td> </tr> <tr> <td class="subtitle1_single">Antiviral</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>HSV and VZV</strong></td> </tr> <tr> <td class="indent2">Acyclovir <ul class="decimal_heading"> <li>For HSV: 400 or 800 mg orally twice daily </li> <li>For VZV: 800 mg orally twice daily </li> </ul> </td> </tr> <tr> <td class="indent2">Valacyclovir 500 mg orally twice daily</td> </tr> <tr class="divider_bottom"> <td class="indent2">Famciclovir 250 mg orally twice daily</td> </tr> <tr class="divider_bottom"> <td class="indent1"><strong>CMV</strong><sup>Δ</sup></td> </tr> <tr> <td class="indent2">Valganciclovir 900 mg orally once daily with food</td> </tr> <tr class="divider_bottom"> <td class="indent2">Ganciclovir 5 mg/kg IV once daily</td> </tr> <tr> <td class="subtitle1_single"><em>Pneumocystis</em></td> </tr> <tr> <td class="indent1"><strong>Preferred regimen:</strong></td> </tr> <tr> <td class="indent2">Trimethoprim-sulfamethoxazole one single-strength tablet orally once daily <strong>or</strong> one double-strength tablet orally once daily or three times weekly<sup>◊</sup></td> </tr> <tr> <td class="indent1"><strong>Alternative regimens:</strong> </td> </tr> <tr> <td class="indent2">Dapsone 100 mg orally once daily or 50 mg orally twice daily</td> </tr> <tr> <td class="indent2">Pentamidine 300 mg by aerosol every four weeks</td> </tr> <tr> <td class="indent2">Atovaquone 1500 mg orally once daily with a high-fat meal</td> </tr> </tbody></table></div><div class="graphic_lgnd">The doses above are intended for patients with normal renal function. The doses of many of the agents listed above must be adjusted in the setting of renal insufficiency. Many of the agents listed above can be given IV if the patient is unable to take oral medications. Refer to the Lexicomp drug specific monograph for renal dose adjustments and IV dosing.</div><div class="graphic_footnotes">HSV: herpes simplex virus; 

	VZV: varicella-zoster virus; 

	CMV: cytomegalovirus; 

	IV: intravenously.<br/>	

	* Refer to the associated topic review for indications for antimicrobial prophylaxis.<br/>	

	¶ Posaconazole and voriconazole are potent inhibitors of CYP3A4 drug metabolism; fluconazole is a moderate inhibitor. Adjustment of antineoplastic therapy may be required. Readers may use Lexi-Interact, the drug interactions program included with UpToDate to determine specific interactions.<br/>	

	Δ Regular cytomegalovirus (CMV) surveillance testing followed by preemptive anti-CMV therapy for a positive result may be preferred over prophylaxis and is discussed in the topic review on prevention of infections in patients with CLL, section on alemtuzumab. Note that the dosing and schedule for preemptive anti-CMV therapy differs from the prophylaxis dosing shown in this table.<br/>	

	◊ Trimethoprim-sulfamethoxazole is preferred as it is the most effective regimen for <em>Pneumocystis</em> prophylaxis. It also provides activity against <em>Toxoplasma gondii</em> as well as certain bacteria (<em>Nocardia</em> spp, <em>Listeria</em> spp, some pneumococci).</div><div id="graphicVersion">Graphic 95619 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
